Melanoma

Intralesional Rose Bengal in melanoma elicits tumor immunity via HMGB1
Hao Liu, Krithika Kodumudi, Amy Weber, John Robinson, Satoshi Nemoto, Georgina Crago, Timothy McCardle, Erica Royster, Amod A Sarnaik, Shari Pilon-Thomas

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P408; DOI: 10.1186/2051-1426-3-S2-P408
Measurement of PD-L1 in melanoma: a quantitative antibody comparison
Joel C Sunshine, Sneha Berry, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova, Toby Cornish, Evan J Lipson, Robert A Anders, Janis M Taube

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P107; DOI: 10.1186/2051-1426-3-S2-P107
Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Diana Giannarelli, Marco Palla, Corrado Caracò, Marcello Curvietto, Assunta Esposito, Miriam Paone, Giovanni Rinaldi, Maria Chiara Grimaldi, Nicola Mozzillo, Paolo A Ascierto

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P134; DOI: 10.1186/2051-1426-3-S2-P134
Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
Kathan Mehta, Leonard Appleman, Hong Wang, Ahmad Tarhini, Rahul Parikh

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P234; DOI: 10.1186/2051-1426-3-S2-P234
Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling
Stefani Spranger, Brendan Horton, Thomas F Gajewski

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P418; DOI: 10.1186/2051-1426-3-S2-P418
A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
Walter Urba, Bartosz Chmielowski, Deryk Loo, Jan Baughman, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Naiyer Rizvi

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P176; DOI: 10.1186/2051-1426-3-S2-P176
Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
Cristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitrii Romaniuk, Lukasz Kuryk, Teea Sarvela, Andrea Vitale, Maxim Antopolsky, Aniket Magarkar, Tapani Viitala, Teemu Suutari, Alex Bunker, Marjo Yliperttula, Arto Urtti, Vincenzo Cerullo

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P333; DOI: 10.1186/2051-1426-3-S2-P333
Elucidating the role of Neuropilin-1 in intra-tumoral regulatory T cell stability
Abigail E Overacre, Maria Chikina, Greg M Delgoffe, Dario AA Vignali

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P274; DOI: 10.1186/2051-1426-3-S2-P274
Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
Ileana S Mauldin, Nolan A Wages, Anne M Stowman, Ena Wang, Mark E Smolkin, Walter C Olson, Donna H Deacon, Kelly T Smith, Nadejda Galeassi, Jessica E Teague, Rachael A Clark, Francesco M Marincola, Gina R Petroni, David W Mullins, Craig L Slingluff

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P139; DOI: 10.1186/2051-1426-3-S2-P139
Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
Ronald J Fecek, Simeng Wang, Walter J Storkus

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P432; DOI: 10.1186/2051-1426-3-S2-P432

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages